Nepexto (Etanercept)

• Nepexto (etanercept) targets the TNF‑α pathway, a central driver of inflammatory arthritis and related skin disease.
• Rheumatoid arthritis: reduces joint inflammation, pain, and stiffness while slowing radiographic progression of joint damage.
• Psoriatic arthritis: improves joint swelling, pain, and skin lesions, leading to better functional outcomes.
• Ankylosing spondylitis: alleviates spinal pain and stiffness, enhancing mobility and quality of life.
• Plaque psoriasis: decreases erythema, scaling, and plaque thickness, resulting in clearer skin.

• Etanercept is a recombinant fusion protein that combines the extracellular ligand‑binding portion of the human TNF receptor 2 with the Fc region of IgG1. After subcutaneous administration it circulates in the bloodstream and binds soluble TNF‑α as well as lymphotoxin‑α (TNF‑β), preventing these cytokines from interacting with cell‑surface TNF receptors. This blockade interrupts downstream inflammatory signaling cascades, reducing production of other pro‑inflammatory mediators and attenuating chronic immune‑mediated inflammation.

Etanercept may be associated with a range of adverse reactions, which are commonly categorized by frequency and severity.

Common Side Effects

• Injection site reactions: redness, swelling, or pain at the injection site.
• Upper respiratory tract infection: nasopharyngitis, sinusitis, or sore throat.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects

• Serious infections: tuberculosis, bacterial sepsis, or opportunistic fungal infections.
• Malignancies: lymphoma or other rare cancers.
• Demyelinating disorders: multiple sclerosis‑like events.
• Autoimmune phenomena: drug‑induced lupus or vasculitis.

• Prior to initiating Nepexto, clinicians should evaluate several safety considerations to minimize risk.
• Screen for active infection: assess and treat any bacterial, viral, or fungal infection before starting therapy.
• Test for latent tuberculosis: perform TB screening (e.g., interferon‑γ release assay) and provide prophylaxis if positive.
• Monitor hepatitis B status: check serology and manage chronic infection according to guidelines.
• Avoid live vaccines: do not administer live attenuated vaccines during treatment or for several weeks after discontinuation.
• Pregnancy and lactation: safety data are limited; use only if potential benefit justifies potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Etanercept can interact with other medicines, influencing efficacy or safety, and should be reviewed before co‑administration.

Major Interactions (Avoid)

• Live attenuated vaccines: may cause uncontrolled infection due to immunosuppression.
• Concurrent use with other biologic immunosuppressants (e.g., infliximab, adalimumab): increases risk of severe infections.

Moderate Interactions (Monitor Closely)

• Immunosuppressive agents (e.g., methotrexate, azathioprine): may enhance immunosuppression; monitor infection signs.
• Anticoagulants (e.g., warfarin): rare reports of altered INR; check coagulation parameters periodically.
• Cytochrome P450 substrates: etanercept does not significantly affect CYP enzymes, but monitor drugs with narrow therapeutic windows.